Aclaris Therapeutics
ACRS
33 hedge funds and large institutions have $277M invested in Aclaris Therapeutics in 2015 Q4 according to their latest regulatory filings, with 33 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$74.1M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$50M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$32.2M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$17.5M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$12.6M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $45K | +$32.3K | +1,660 | New |
|
27
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $38K | +$28.2K | +1,446 | New |
|
28
BNP Paribas Financial Markets
Paris,
France
| $28K | +$20.2K | +1,038 | New |
|
29
Barclays
London,
United Kingdom
| $26K | +$19.5K | +1,000 | New |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| $22K | +$15.8K | +812 | New |
|
31
Morgan Stanley
New York
| $11K | +$7.62K | +391 | New |
|
32
Bank of America
Charlotte,
North Carolina
| $4K | +$2.71K | +139 | New |
|
33
UBS Group
Zurich,
Switzerland
| $3K | +$2.12K | +109 | New |
|
ACRS Hedge Fund Activity: Q4 2015 in Review
33 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2015, worth a combined $277M.
Buyers outnumbered sellers: 33 funds opened new ACRS positions and 0 closed out — a net gain of 33 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $74.1M.
- 33 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2015, up from 0 in Q3 2015.
- Funds reported $277M of Aclaris Therapeutics stock for Q4 2015.
- 33 funds opened new Aclaris Therapeutics positions in Q4 2015 and 0 closed out, a net change of +33 holders.
- The largest Aclaris Therapeutics buyer in Q4 2015 was Fidelity Investments, an estimated $74.1M added.
Based on aggregated 13F filings for Q4 2015.